Effect of DNA methylation status on first-line anti-epidermal growth factor receptor treatment in patients with metastatic colorectal cancer

被引：0
|
作者：
Hiroki Osumi
Kota Ouchi
Eiji Shinozaki
Shin Takahashi
Akira Ooki
Izuma Nakayama
Takeru Wakatsuki
Mariko Ogura
Daisuke Takahari
Keisho Chin
Kensei Yamaguchi
Chikashi Ishioka
机构：
[1] Cancer Institute Hospital,Department of Gastroenterology
[2] Japanese Foundation for Cancer Research,Department of Medical Oncology
[3] Tohoku University Hospital,Department of Clinical Oncology
[4] Tohoku University Graduate School of Medicine,undefined
来源：
International Journal of Colorectal Disease | 2022年 / 37卷
关键词：
DNA methylation; Epidermal growth factor receptor inhibitor; Metastatic colorectal cancer; Predictive biomarker;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：1439 / 1447
页数：8
相关论文
共 50 条
  • [21] Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer
    Hecht, J. Randolph
    Douillard, Jean-Yves
    Schwartzberg, Lee
    Grothey, Axel
    Kopetz, Scott
    Rong, Alan
    Oliner, Kelly S.
    Sidhu, Roger
    CANCER TREATMENT REVIEWS, 2015, 41 (08) : 653 - 659
  • [22] Efficacy and safety of anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy for metastatic colorectal cancer in first-line and second-line therapies: a meta-analysis
    Wang, Hongchi
    Ma, Bin
    Gao, Peng
    Song, Yongxi
    Xu, Qingzhou
    Hu, Yaoyuan
    Zhang, Cong
    Wang, Zhenning
    ONCOTARGETS AND THERAPY, 2016, 9 : 5405 - 5416
  • [23] A modified MethyLight assay predicts the clinical outcomes of anti-epidermal growth factor receptor treatment in metastatic colorectal cancer
    Ouchi, Kota
    Takahashi, Shin
    Okita, Akira
    Sakamoto, Yasuhiro
    Muto, Osamu
    Amagai, Kenji
    Okada, Takaho
    Ohori, Hisatsugu
    Shinozaki, Eiji
    Ishioka, Chikashi
    CANCER SCIENCE, 2022, 113 (03) : 1057 - 1068
  • [24] IN VIVO IMMUNOLOGICAL EFFECTS OF ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) THERAPY IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS
    Chatzileontiadou, S.
    Rovati, B.
    Mariucci, S.
    Loupakis, F.
    Bencardino, K.
    Manzoni, M.
    Delfanti, S.
    Valentino, F.
    Ricci, V
    Brugnatelli, S.
    Ronzoni, M.
    Falcone, A.
    Danova, M.
    ANNALS OF ONCOLOGY, 2009, 20
  • [25] Combining Anti-epidermal Growth Factor Receptor (EGFR) Therapy with Immunotherapy in Metastatic Colorectal Cancer (mCRC)
    Xiong, Feng
    Zhou, Yu-Wen
    Hao, Ya-Ting
    Wei, Gui-Xia
    Chen, Xiao-Rong
    Qiu, Meng
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2024, 18 (4-5) : 185 - 192
  • [26] Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: A meta-analysis
    Qi-Bin Song
    Qi Wang
    Wei-Guo Hu
    World Journal of Gastroenterology, 2015, (14) : 4365 - 4372
  • [27] Cetuximab, A Chimeric Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in Colorectal Cancer Treatment
    Martinelli, Erika
    Orditura, Michele
    De Vita, Ferdinando
    Galizia, Gennaro
    Ciardiello, Fortunato
    CURRENT CANCER THERAPY REVIEWS, 2007, 3 (04) : 242 - 248
  • [28] Biomarkers for Predicting the Efficacy of Anti-Epidermal Growth Factor Receptor Antibody in the Treatment of Colorectal Cancer
    Okada, Yasuyuki
    Miyamoto, Hiroshi
    Goji, Takahiro
    Takayama, Tetsuji
    DIGESTION, 2014, 89 (01) : 18 - 23
  • [29] Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: A meta-analysis
    Song, Qi-Bin
    Wang, Qi
    Hu, Wei-Guo
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (14) : 4365 - 4372
  • [30] Real-World Data Analysis of Second-Line Antiangiogenic Targeted Treatments Following Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and First-Line FOLFOX for Patients with Metastatic Colorectal Cancer
    Satake, Hironaga
    Kagawa, Yoshinori
    Shinozaki, Eiji
    Tanizawa, Yoshinori
    Jin, Long
    Cai, Zhihong
    Makiyama, Akitaka
    ADVANCES IN THERAPY, 2022, 39 (06) : 2596 - 2613
12345